Top Markets
#1 Black Phoenix Black Phoenix +745.14%
#2 Beam Beam +42.80%
#3 Bless Bless +20.59%
#4 THORChain THORChain +20.28%
#5 SAFEcoin SAFEcoin +17.38%
#6 EfficientFrontier EfficientFrontier +17.25%
#7 MiL.k Alliance MiL.k Alliance +17.12%
#8 TENDIES TENDIES +15.99%
#9 THORChain Yield THORChain Yield +15.41%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +14.85%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
株式のランク #5577
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
株価
$36.98
最終同期: 2026-08-26
時価総額
$2.58B
変化（1日）
-0.67%
変化（1年）
55.51%
国
NL
取引 Pharvaris N.V. (PHVS)

カテゴリー

Healthcare
Pharvaris N.V.（PHVS）のP/S比率
2026 時点のP/S比率 TTM: 0
Pharvaris N.V. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0 です。2026 年末時点でのP/S比率は 0 でした。
Pharvaris N.V. の P/S 比率の履歴（2026 ～ 2026）
各年末時点のP/S比率
年 P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH